A s p a r t y l g l u d d a s e (AGA: E.C. 3.5.1.26) is a lysosomal amidase that hydrolyzes the N-acetylgluaxmhe-asparaghe linkage as one of the final steps in the breakdown of glycoproteins. Deficiency of this enzyme results in aspartylglucosaminuria (AGU), an inherited lysosomal storage disease. h an attempt to establish the tissue-specific expression of AGA in normal individuals and in AGU patients, we adapted biochemical and immunohistochemical techniques to analyze AGA polypeptides in human cells and tissues. The biochemical analysis revealed the existence of U-and P-subunit structures of AGA in all tissues. Immunohistochemical staining demonstrated a cell specificity in the distribution of AGA: immunoreactivity was strongest in hepatocytes, pyramidal cells in the cerebral cortex, and proximal tubule cells in the kidney. In tissues from AGU patients,
Introduction
Aspartylglucosaminidase [AGA: N4-(P-N-acetylglucosaminyl)-t asparaginase, glycoasparaginase, glycosylasparaginase: E.C. 3.5.1.26) is a lysosomal amidase that hydrolyzes the amide bond between the residual N-acetylglucosamine and asparagine during the degradation of mammalian glycopeptides and glycoproteins (Makino et al., 1966) . Deficient activity of AGA results in a lysosomal storage disease, aspartylglucosaminuria (AGU) (McKusic, 1992 ) (MIM n:o 208400) an inborn error of metabolism characterized by progressive intralysosomal accumulation of uncleaved aspartylglucosamines Supported by grants from the Academy of Finland, the Rinnekoti Research Foundation, and the Orion and Farmos Foundations.
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AGA immunoreactivity could be detected in hepatocytes and in proximal tubule cells but not in the pyramidal cells. The regulation of the expression of AGA was approached by analyzing the transcript levels and the methylation of the AGA gene. Both heavy methylation of the AGA gene and the constant level of AGA " A were typical of a "househ o l d type of enzyme that can be found in small quantities in all tissues. This was in contrast to the variability of the amount of AGA polypeptides observed in different cells and tissues, suggesting that the expression of AGA is regulated not at the transcriptional but rather at the translational level. (J Histochem Cytdem 41: [981] [982] [983] [984] [985] [986] [987] [988] [989] 1993) folded AGA protein in the ER and cis-Golgi region and to the early degradation of the mutated polypeptide chain (Enomaa et al., 1992; Ikonen et al., 1991b) .
The enzymatic activity of AGA has been demonstrated in many mammalian tissues including pig serum, rat and hog kidney, and in rat, mouse, pig, cow, and chicken liver (Tollersrud and Aronson, 1992; Tollersrud and Aronson, 1989; Kohno and Yamashha, 1972; Makino et al., 1968; Mahadevan and Tappel, 1967) . Human AGA has been purified to homogeneity from liver and leukocytes Kaartinen et al., 1991; Baumann et al., 1989) . The human AGA enzyme is synthesized as a 42 KD polypeptide, which is rapidly post-translationally processed into two non-covalently linked 24 KD ( a ) and 17 KD (p) subunits Ikonen et al., 1991a) . This proteolytic cleavage is an activation step and takes place in the endoplasmic reticulum (Ikonen et al., 1993) . Information on the expression of AGA in human tissues has been based on measurements of AGA activity, and no detailed biochemical or histochemical data on the tissue distribution of AGA have been published thus far. The significance of these analyses is emphasized by the fact that lysosomal storage diseases such as AGU are considered candidate disorders for gene therapy. Before animal in vivo expression patterns are justified, it is essential to characterize the expression patterns of the AGA protein in normal human tissues and also to determine the aberrations found in AGU patients.
Here we report the expression of the AGA polypeptide chains in various human tissues obtained both from control individuals and from AGU patients, with special emphasis on the analyses of tissues that have been shown to possess significant enzymatic activity or which express phenotypic symptoms in AGU.
Materials and Methods
Tissue Specimens. Brain and liver tissue from control subjects and AGU patients were obtained from autopsy material. The post-mortem delay was the same (12 hr) in controls and AGU patients. The expression of AGA in normal connective tissue and striated muscle was analyzed in a biopsy specimen from oral mucosa.
Preparation of the Specimens for Immunoperoxidase Staining. The tissue specimens were fixed with 10% neutral buffered formalin, dehydrated through an increasing ethanol series and xylene, embedded in paraffin, and cut into sections 6 pm thick on 3-aminopropyldiethoxysilane (APE) (Sigma; St Louis, MO)-coated slides. In some experiments, frozen oral mucosa tissue was used. Immediately after removal, these specimens were frozen in liquid nitrogen and embedded in Tissue-Tek I1 OCT embedding medium (Miles Laboratories; Naperville, IL). Cryotome sections were cut, collected on APE-coated slides, air-dried for 30 min, fixed with cold acetone for 10 min, and stored at -20°C.
Antibodies. Antisera against the native AGA and the denatured 17 and 24 KLI subunits were produced in rabbits and characterized as described earlier (Enomaa et al., 1992; Halila et al., 1991) .
Enzymatic Pre-treatment. To overcome the potential masking effect caused by formalin fixation of the tissues, the rehydrated paraffin sections were pre-treated with pepsin (Merck; Darmstadt, Germany) 0.4% in 0.01 mollliter HCI for 40-120 min at 37°C. To control the effect of the enzymatic pre-treatment, unpepsinized sections were also used.
Immunostaining. Paraffin sections were rehydrated through xylene and a decreasing ethanol series and washed with phosphate-buffered saline (PBS: 145 mM NaCI, 10 mM phosphate buffer, pH 7.4) three times for 10 min.
To inhibit endogenous peroxidase activity, the sections were pre-treated with 0.3% Hz02 in methanol for 30 min and again washed with PBS (three times for 5 min). Immunohistochemical staining was performed according to the instructions of the Vectastain peroxidase rabbit ABC kit (Vector Laboratories; Burlingame, CA). For staining of paraffin and frozen sections the AGA antibody was used at 1:200 or 1:300 dilution and 1:600 dilution in PBS, respectively. For detailed histological examination, the sections were briefly counterstained with hematoxylin. In some experiments the primary antibody was diluted with PBS containing 2 mg bovine serum albumin (BSA)/ml and the blocking serum and the biotinylated secondary antibody were diluted with PBS containing 20 mg and 1 mg BSA/ml, respectively. The sections were mounted with Glycergel mounting medium (Dakopatts; Glostrup, Denmark). To control the specificity of the staining reactions, rabbit pre-immune serum and PBS were substituted for the specific primary antibodies.
DNA Hybridization Studies. High molecular weight DNA was extracted with repeated phenol-chloroform extractions modified from Vanderplas et al. (1984) . Special precaution was taken to avoid an increase in salt concentration because this interfered with the digestions. Approximately 10 pg of DNA was digested with Hpa I1 (12 UIpg DNA) (New England Bio-Labs; Beverly, MA) or Msp I (20 U/ pg DNA) (New England Bio-Labs, internal control) restriction endonucleases for at least 16 hr. To ensure complete cleavage, additional Hpa I1 at 6 U/ pg DNA was added, and the digestion was continued for an additional 2 hr. After digestion the samples were electrophoresed through 0.8% agarose gels, transferred to nylon filters (Hybond N) (Amersham; Poole, UK), and hybridized with the AGA cDNA probe in standard conditions (Maniatis et al., 1982) . The completeness of the Hpa I1 digestion was controlled by hybridizing the filters with an L-myc probe (a kind gift from Doctors K. Alitalo and T. Mikela, University of Helsinki, Laboratory of Cancer Biology, Helsinki, Finland). The probe was labeled by random priming (Feinberg and Vogelstein, 1983 ) (Bethesda Research Laboratories; Gaithersburg, MD) using [32P]-cytosine and guanine nucleotides (Amersham). Hybridization patterns were visualized by autoradiography on Kodak XAR 2 X-ray film at -80°C for 1-3 days.
RNA Hybridization Studies. The brain, liver, and muscle tissue samples were autopsy material from an 11-month-old infant who died of a congenital heart disease. Total cellular RNA was extracted from the tissue samples and cultured fibroblasts by the guanidine isothiocyanate method (Chirgwin et al., 1979) and poly (A)' selected RNA was prepared using oligo(dT) cellulose chromatography. For Northern blot analyses (Alwine et al., 1977) , 1 pg of poly(A)+ RNA was electrophoresed in a 0.8% agarose gel containing formaldehyde, transferred to a nitrocellulose membrane (Hybond-C extra; Amersham), and hybridized to a 32P-labeled AGA cDNA under conditions recommended by the manufacturer. After washing, the filter was exposed to a Kodak XAR X-ray film at -80°C for 2 days. Enzyme Assay. AGA activity was measured by detecting the release of N-acetylglucosamine from the substrate 2-acetamido-1-B-(~-aspartamido)-1,2-dideoxy-B-D-glucose (AADG) (Sigma) as described by Makino et al. (1966) . After incubation for appropriate time intervals at 37'C in a final volume of 20 pl, the reaction was stopped by adding 50 pI of 0.25 M sodium borate buffer, pH 8.8, and heating at 100°C for 3 min. One unit of enzyme activity was defined as the amount of enzyme that liberates 1 pmol of N-acetylglucosaminelmin at 37°C. Partial Purification of Aspartylglucosaminid. AGA was partially purified from 5-10 g of brain, kidney, liver, lung, muscle, and placenta stored at -70°C for a prolonged time. The tissues were homogenized in a fourto fivefold volume of PBS containing 0.5% Triton X-100. 0.1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM N-ethylmaleimide (NEM). The unsoluble cell material was centrifuged down with a Sorvall GSA rotor at 12,000 rpm for 45 min. The supernatant was collected and heated at 60-C for 15 min and the precipitated protein was removed by centrifuga-tion at 12,000 rpm for 10 min. The supernatant was again collected and dialyzed against PBS overnight at 4°C. After the dialysis, the protein concentration of the dialysate was adjusted to 20 mg/ml or less with PBS; sodium dodecyl sulfate (SDS) was added to the 3% final concentration and the dialysate was then warmed to 46'C for 20 min. Ammonium sulfate was added to the dialysate to a 35% final concentration (208 mg/ml) at room temperature. The solution was immediately centrifuged for 10 min at 10.000 rpm with a Sorvall RC-5B at room temperature. The brown, gluelike, usually floating pellet was removed first by hand and the remaining insoluble material by vacuum filtration through pre-wet Whatman 3 filter paper. The clear supernatant was dialyzed at RT against PBS for at least 4 hr. The dialysate was concentrated with a D i d o filtrator and Amicon PM-30 (Amicon; Danvers, MA) membrane to 5 ml and was then subjected to Bio-Gel P-100 gel filtration. The flow rate was 15 ml/hr, and 5 ml fractions were collected. Fractions with the highest enzyme activity were pooled and concentrated in an Amicon Centricon PM-10 concentrator to 500 PI. Immunoprecipitation of the serum Bio-Gel fractions demonstrating activity was carried out using antibodies prepared against the native AGA enzyme as previously described (Ikonen et al., 1991b) . Digestions of AGA polypeptides with N-glycosidase F were carried out as described by Halila et al. (1991) .
The glycoprotein fractions from brain, fibroblast, liver and muscle were obtained by concanavalin A-Sepharose chromatography of the respective tissue homogenates. The homogenates were loaded at a flow rate of 0.8 ml/min onto a concanavalin A-Sepharose (10 mg of concanavalin Alml) (Pharmacia Fine Chemicals; Piscataway, NJ) column (1.5 cm x 7 cm) equilibrated with PBS. AGA was bound to the column and was then eluted with PBS containing 0.1 M methyl a-mannoside. Fractions with AGA activity were pooled and the methyl a-mannoside in the eluate was removed by concentration of the enzyme three times with PBS using an Amicon PM-10 membrane.
Immunoblotting. Partially purified AGA was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on an 8-25 % Phastgel (Pharmacia). After gel electrophoresis, the gel was overlaid with a pre-wetted poly(viny1idene difluoride) (PVDF) membrane (Immunobilon) (Millipore; Bedford, MA) and the blotting was carried out by diffusion at 70°C for 2 hr. The membrane was blocked for 30 min with 1% BSA in 10 mM =is-HC1, pH 8.0, containing 0.15 M NaCl and 0.05% Tween-20, and then incubated in 1200 diluted 24 KD antiserum and 1:400 diluted 17 KD antiserum in the same buffer for 30 min at room temperature (ProtoBlot Western Blot AP System) (Promega; Madison, WI).
SDS-PAGE on the glycoprotein fractions of brain, fibroblast, liver, and muscle was carried out as described by Laemmli (1970) . Polyacrylamide 4% was used in the stacking gel and polyacrylamide 12% in the separating gel. After the gel electrophoresis the proteins were transferred to nitrocellulose (Hybond C extra; Amersham) and the immunostaining was performed as described above.
Results

Immunohistochemistry
We raised antibodies in rabbits against both the native AGA enzyme and denatured AGA subunits . These antibodies were tested for immunostaining of tissue sections. The antibodies against the denatured subunits resulted in reliable detection of the AGA protein even in the paraffin sections, and the staining patterns obtained with the antibody to the 24 KD subunit were interpreted as characterizing the tissue distribution of AGA. Pretreatment of the sections with pepsin was needed to facilitate the staining reactions. The control sections treated with the pre-immune rabbit sera were negative (Figures la-lc). Normal Tissues. The immunohistochemical studies were performed on sections of paraffin-embedded autopsy or biopsy specimens from cerebral cortex, oral mucosa, kidney, liver, and skeletal muscle obtained from individuals at ages ranging from 30-40 years. Immunostaining for AGA could be detected in all tissues analyzed, but the intensities of the staining reactions varied from one tissue and cell type to another. A punctate staining pattern was obvious in the cytoplasm of all immunoreactive cells, in agreement with the lysosomal location of AGA. The strongest immunoreactivity of the AGA enzyme was observed in hepatocytes, tubule cells of the kidney, and pyramidal cells of the cerebral cortex. Capillary endothelial cells, fibroblasts of the subepithelial connective tissue of the oral mucosa, and striated muscle fibers demonstrated weaker immunostaining.
In liver, which is considered the main producer of the circulating AGA protein, the hepatocytes stained very strongly and the staining exhibited a uniformly granular pattern. The sinusoidal and Kupffer cells did not show any immunostaining ( Figure Id) , but fibroblasts and vascular endothelial cells in the capsule and septal regions exhibited weak cytoplasmic immunoreactivity. Immunostaining in the cerebral cortex was also heterogeneously distributed. The strongest reactivity was found in the pyramidal cells and especially in the soma of these cells, whereas the neuron extensions displayed considerably weaker immunostaining. The staining of neuroglial cells was consistently less intense than that observed in neurons (Figure le) . In kidney, the cells lining the proximal tubules exhibited the most intense immunostaining. Detectable but weaker immunoreactivity against AGA protein could also be seen in other tubule cells. No immunoreactive material was detected in the cells of Bowman's capsule (Figure lf) . AGU Tissues. Tissue samples from AGU patients were paraffinembedded specimens from the obductions of one 40-and one 50year-old patient. The presence of the AGA antigen was documented by staining with AGA antibodies. Only tissues that demonstrated morphologically or immunohistochemically significant differences from the normal tissues are described.
The typical histopathological manifestation of AGU, the cytoplasmic vacuolization produced by enlarged lysosomes, was obvious in tissue sections from both patients. However, there was a dramatic difference in the morphological appearance of the cells between the older and the younger patient. The cytoplasmic vacuoles, although clearly evident in the cells of the younger patient, were even more striking in the cells of the older patient. In the latter case the cell boundaries were almost indistinguishable and the amount of residual cytoplasm was negligible. The immunostaining pattern of the remaining cytoplasm of both patients' cells appeared to be homogeneous rather than punctate.
Hepatocytes from the younger AGU patient expressed the AGA antigen relatively strongly, but the granular pattern of immunostaining was not as obvious as in normal hepatocytes. Virtually no reactivity was present in capsule fibroblasts ( Figure Ig) . The hepatocytes of the older patient were extensively filled with large cytoplasmic vacuoles, but homogeneous immunoreactivity of AGA was still detected in the residual cytoplasm (Figure lj) . In contrast to the findings in the normal brain tissue, the pyramidal cells of the cerebral cortex displayed no reactivity in either of the two AGU patients, indicating scarcity of the AGA antigen (Figures 1h and  1k ). In the kidney of the younger patient, the cytoplasm of the proximal tubular cells was slightly vacuolated, but the pattern and the intensity of immunostaining for AGA still resembled those in the normal kidney (Figure li) . In the sections from the older patient's kidney, AGA was visualized only in the vacuolated cells of the proximal tubules ( Figure 11 ).
AGA Protein in Tissue Homogenate5 from Control Individuals and AGU Patients
When the specific activity of AGA was measured in tissue homogenates, the highest activity, 0.36 mU/mg protein, was obtained from the leukocyte homogenate. This was on average 1.5-fold greater than the specific activity in the liver or lung and about six-fold greater than in the kidney and placenta. The specific activity of AGA in the brain and muscle was less than 10% of that found in leukocytes. Serum and fibroblasts contained the lowest AGA activity. The enzyme activity in serum was barely detectable, being about 1.5 pUlmg protein (Figure 2) . These results were in accordance with the results of Western blot analysis of the concanavalin A-separated glycoprotein fractions from the brain, fibroblasts, liver, and muscle: the strongest signal was obtained from the glycoprotein fraction of the liver, whereas a barely detectable signal was obtained from brain and fibroblasts ( Figure 3A) .
For structural analysis of the AGA polypeptides, the enzyme was partially purified from all the analyzed tissues. We developed a rapid three-step purification procedure that utilizes the exceptional SDS resistance of AGA and includes homogenization and heating, a salting step with 35% (NH4)2S04 in the presence of 3% SDS and Bio-Gel gelfiltration ( 0 -K Tollersrud, personal com- AGA activity in all tissues analyzed. Because of the high protein concentration and low specific activity of AGA in human serum, an additional concanavalin A step was added before the Bio-Gel gel filtration when AGA was purified from this source, and the fractions demonstrating activity were immunoprecipitated with the antibody against the native AGA enzyme. After this partial purification, the samples were subjected to Western blot analysis, which revealed the existence of both the a-and the P-subunit of AGA in all tissues. However. some variation in the migration rate of the AGA polypeptides from different tissues could be observed (Figure 4A) . Further deglycosylation experiments with N-glycosidase F revealed that these differences in molecular weight were due to variations in the degree of glycosylation (Figure 48) .
The enzymatic assays of AGA activity in the tissue samples of the AGU patients revealed that the only tissue containing any residual AGA activity was the liver. However, the specific activity was less than 5% of that found in normal liver. Brain and kidney homogenates showed no detectable AGA activity (Figure 2) . The three-step purification procedure described a h was also applied to brain, kidney, and liver obtained from the autopsy samples of AGU patients. Western blot analysis gave a weak signal of both a-and &subunits in kidney and liver samples (Figure 4C) . but no signal was obtained in the brain sample.
RNA and DNA AnaZyses
Total RNA was isolated from brain, liver. and muscle tissues obtained at autopsy of an 11-month-old infant within 24 hr of death. as well as from cultured skin fibroblasts. Poly-(A)* mRNA was isolated using oligo-dT cellulose and was analyzed by Northern blotting and hybridization, with the AGA cDNA as a probe. When 1 vg of oligo-(dT)-selected poly(A)* RNA from the brain, fibroblasts, liver, and muscle was hybridized with the AGA cDNA, the obtained hybridization signals were very weak and of about equal intensity in all the samples from different tissues. The size of the visualized AGA mRNA population was also constant, about 2.1 KB, corresponding to the length of the AGA cDNA (Ikonen et al., 1991a) (Figure 3B) . The hybridization signals obtained from RNA samples of AGU patients' fibroblasts did not differ quantitatively or qualitatively from those obtained in control samples (data not shown).
The methylation of the AGA gene in both control subjects and AGU patients was studied using genomic DNA from the control brain, placenta, and liver and from AGU liver. The DNA was digested with Hpa 11, a restriction endonuclease sensitive to DNA methylation, (the methylation-insensitive isoschizomer Msp I was used as control) and subjected to Southern blotting. The fragments produced by the Hpa I1 digestion were all larger than 10 KB, whereas the MSP I digests resulted in six fragments ranging from 1-8 KB. This suggests that all the HpaII sites of the AGA gene were methylated in all analyzed tissues, and no obvious differences in the methylation level either between different tissues or samples from control and AGU individuals could be detected ( Figure 5 ).
Discussion
Evaluation of the tissue-specific expression of human AGA has been hampered by the very small amount of this lysosomal enzyme in tissues. Earlier comparison studies of human AGA in different tissues have been based only on the measurement of the specific activities of AGA (Dugal, 1977; Palo et al., 1972) . We have recently succeeded in purifying significant amounts of the AGA enzyme from human leukocytes . which enabled the production of AGA-specific antibodies against both the native enzyme and its denatured subunits. With the help of these antibodies a more detailed study of the expression of AGA in different tissues could be performed. As expected, the immunohistochemical stainings revealed the presence of AGA in all normal tissues analyzed. However, AGA was seen to accumulate in specific cell types within a single organ. For example, in the cerebral cortex the pyramidal cells were found to contain the highest amounts of AGA, and in the kidney the proximal tubule cells were much more intensely stained than other tubule cells or the cells of Bowman's capsule. In addition to pyramidal and proximal tubule cells, the hepatocytes effectively expressed the AGA protein. The relative intensities of immunostaining for AGA in various tissues agreed both with the specific activities measured from tissue homogenates and with the results obtained by densitometric scanning of the bands in Western blot analyses of corresponding tissue homogenates. This is exemplified by the small number of immunopositive cells observed in the brain, which agrees well with the low specific AGA activity detected in brain tissue and with the weak signal of AGA in the corresponding Westem blot analysis. Analogously. the intensive staining of hepatocytes is in agreement with the high specific AGA activity in liver homogenate and with the strong signal obtained from the liver in Westem blotting. The Western blot analyses of AGA subunits from the partially purified enzyme preparations revealed no evidence for the existence of structurally different isoenzymes of AGA in different tissues. lmmunoblotting confirmed the presence of both the a-and &subunit in all tissues, and only glycosylation differences could be observed among the tissues analyzed. The most dramatic phenotypic features of AGU. like those of several other lysosome-accumulation diseases. arise from dysfunction of the central nervous system (CNS). When the cerebral cortex of the AGU patients was analyzed by immunohistochemistry and immunoblotting. no immunoreactive material could be found. Assuming that the tissues obtained from fresh autopsies reflect the actual situation in vivo, these results agree well with the clinical features observed in AGU. Clarification of the mechanisms that apparently degrade the AGA protein in CNS cells would be of great importance when the therapy of AGU patients is considered. In contrast to the findings in brains of AGU patients, immunocytochemical staining revealed the existence of immunoreactive material in proximal tubule cells and hepatocytes. The intensity of the staining reaction in these regions corresponded to that observed in control tissues. Similarly, in Westem blot analysis both the aand the P-subunit of AGA could be detected in all AGU tissues except brain, but the signal was significantly weaker than in control tissues. This indicates that in the patients' cells and tissues a minor fraction of the mutated AGA protein is normally processed to subunits and presumably reaches lysosomes. This would be in accordance with our previous results from in vitro expression analyses of the corresponding in vitro-mutagenized AGA protein in COS cells (Ikonen et al., 1991b) .
The methylation of the AGA gene was extensive, and no differences in the methylation ofthe Hpa I1 sites could be detected among different tissues or between samples from AGU patients and controls. This methylation pattem is typical of genes that code for "household" type proteins, which demonstrate a constant but low level of expression in all tissues. The transcriptional level of the AGA gene also seemed to be independent of the tissue analyzed. at least at the sensitivity level of Northern hybridization. We have also carried out numeric quantitation of AGA mRNA molecules from MIious human tissues using the PCR-based. solid-phase minisequencing method (Ikonen et al.. 1992a ). This method, too, did not reveal order-of-magnitude differences among normal tissues. The minisequencing method was also applied to quantitate AGA mRNA levels in the tissues of AGU patients. These were found to be similar to those observed in control tissues, with the exception of brain, which contained significantly less AGA mRNA than the corresponding control tissue (Ikonen et al.. 1992a ).
On the basis of these observations, a discrepancy exists between the consistency of the transcriptional level of the AGA gene and the amount of AGA polypeptide in different tissues. This suggests that the major determinant that regulates AGA expression resides not at the transcriptional but at the translational level. This hypothesis is further supported by our recent findings on one AGU patient: this patient carries a deletion that removes the majority of the 3' untranslated region (UTR) but that leaves the coding region of the AGA mRNA intact. Her cells contain a normal amount of truncated and polyadenylated AGA mRNA but only trace amounts of the AGA polypeptide chains (Ikonen et al., 1992b) . The mechanism of translational regulation, including the role of the non-coding regions of the AGA mRNA, is currently under investigation with this AGU patient as a model.
To summarize, in this study the expression of AGA in human tissues was approached for the first time by combined DNA, mRNA, and protein analyses. The household character of AGA could be demonstrated at both the DNA and the mRNA level. but significant differences were observed in the expression of the AGA protein among human cells and tissue types. These differences could not be detected in the amounts of the AGA transcripts in various tissues. Consequently. regulation ofthe expression ofthe AGA gene. unlike that of most human genes, does not appear to take place primarily at the transcriptional level. This information is of essential importance when the future therapy of this disease is considered. The striking absence of immunologically identifiable AGA polypeptide in the brains of AGU patients is in accordance with the cardinal manifestation of the disease, progressive psychomotor retardation. This requires further analyses of the mechanisms involved, but it might be an additional complicating factor when therapeutic interventions are considered, such as enzyme replacement or gene therapy for the disease. However, an encouraging observation from the point of view of any form of replacement therapy for AGU is the observed presence of AGA protein in various tissues from these patients. This suggests that immunological tolerance is present and, therefore, that rejection of exogenous AGA would be unlikely.
